NYMC Faculty Publications
Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence
Author Type(s)
Faculty
DOI
10.1016/j.cpcardiol.2023.102017
Journal Title
Current Problems in Cardiology
First Page
102017
Document Type
Article
Publication Date
1-1-2024
Department
Medicine
Abstract
Direct oral anticoagulants (DOAC) have emerged as a new therapy for patients who need and can tolerate oral anticoagulation. DOACs were initially approved for nonvalvular atrial fibrillation (NVAF) and treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE). Ease of administration, no requirement of bridging with other anticoagulants, and less frequent dosing have made DOACs preferable choice for anticoagulation. Studies are showing promising results regarding use of DOACs beyond the common indications. Studies have been done to show the potential benefit of DOACs in valvular atrial fibrillation, heart failure, acute coronary syndrome, stroke, and peripheral arterial disease. Data have shown safety as well as comparable bleeding incidences with DOACs compared to vitamin K antagonist anticoagulants. Naturally interest is growing to see the use of DOACs apart from the NVAF, DVT, or PE. Authors have highlighted various study results to show the potential beneficial role of DOACs in the above-mentioned situations.
Recommended Citation
Hajra, A., Ujjawal, A., Ghalib, N., Chowdhury, S., Biswas, S., Balasubramanian, P., Gupta, R., & Aronow, W. S. (2024). Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence. Current Problems in Cardiology, 49 (1 Pt A), 102017. https://doi.org/10.1016/j.cpcardiol.2023.102017
